Views & Analysis Navigating the barriers to successful market access The steps required for successful market access.
News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis Six factors shaping healthcare in emerging markets The factors shaping the healthcare landscape in emerging markets.
Views & Analysis UK pharma denied legal challenge to drugs bill cap - updated Rejection of legal challenge an embarrassing blow, and means NHS England free to introduce new budget curbs.
Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
